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Abstract
Right-ventricular function is a good indicator of pulmonary arterial hypertension (PAH) prognosis; however, how the right ventricle
(RV) adapts to the pressure overload is not well understood. Here, we aimed at characterizing the time course of RV early
remodeling and discriminate the contribution of ventricular geometric remodeling and intrinsic changes in myocardial mechanical
properties in a monocrotaline (MCT) animal model. In a longitudinal study of PAH, ventricular morphology and function were
assessed weekly during the first four weeks after MCT exposure. Using invasive measurements of RV pressure and volume, heart
performance was evaluated at end of systole and diastole to quantify contractility (end-systolic elastance) and chamber stiffness
(end-diastolic elastance). To distinguish between morphological and intrinsic mechanisms, a computational model of the RV
was developed and used to determine the level of prediction when accounting for wall masses and unloaded volume measurements
changes. By four weeks, mean pulmonary arterial pressure and elastance rose significantly. RV pressures rose significantly after the
second week accompanied by significant RV hypertrophy, but RV stroke volume and cardiac output were maintained. The model
analysis suggested that, after two weeks, this compensation was only possible due to a significant increase in the intrinsic inotropy
of RV myocardium. We conclude that this MCT-PAH rat is a model of RV compensation during the first month after treatment,
where geometric remodeling on EDPVR and increased myocardial contractility on ESPVR are the major mechanisms by which
stroke volume is preserved in the setting of elevated pulmonary arterial pressure. The mediators of this compensation might
themselves promote longer-term adverse remodeling and decompensation in this animal model.
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Introduction
Pulmonary arterial hypertension (PAH) is a severe disease
of the pulmonary vasculature that is characterized by a rest-
ing mean pulmonary arterial pressure (mPAP) 25mmHg
with a pulmonary arterial wedge pressure 15mmHg.1
During the development of PAH, the right ventricle (RV)
of the heart becomes subjected to pressure overload, which
results in chamber remodeling that initially compensates for
the increase in pulmonary vascular resistance (PVR).
Eventually this response becomes maladaptive and, if left
untreated, PAH results in cardiac decompensation and
heart failure.2 Prior investigations in PAH patients have
indicated that increased RV diastolic stiffness is related to
adverse clinical outcomes3 and reduced survival.4 However,
the process of remodeling and adaptation that the RV
undergoes in response to pulmonary pressure overload is
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not clear, making it harder to determine when the RV goes
from adapting to failure.
To relate pulmonary hemodynamics to right ventricular
mechanics and thereby better characterize the time course of
RV early remodeling during PAH, we carried out a longi-
tudinal study in an animal model of PAH. Using invasive
measurements of RV pressure and volume in a monocrota-
line (MCT) animal model of PAH, ventricular morphology
and function were assessed weekly during the first four
weeks after MCT exposure. To test whether the observed
changes in right ventricular diastolic and systolic function
could be explained by the observed changes in right ven-
tricular preload, afterload, and wall geometry alone, we
compared measured RV pressure-volume (PV) end-diastolic
and end-systolic relations with those predicted by a compu-
tational model that included measured geometrical chamber
remodeling.
RV systolic and diastolic pressures rose significantly after
the second week of PAH induction accompanied by signifi-
cant RV hypertrophy, but RV stroke volume (SV) and car-
diac output (CO) were maintained. The model analysis
suggested that, after two weeks, this compensation was
only possible due to a significant increase in the intrinsic
inotropy of RV myocardium.
Methods
Animal preparation
All experiments were performed with the approval of the
Animal Care and Use Committee at the University of
Illinois, Chicago. The study included 45 male Sprague
Dawley rats weighing 275 12 g (Charles River, Chicago,
IL, USA). PAH was induced in the treatment group by a
subcutaneous injection of 60mg/kg of monocrotaline (crota-
line, Sigma-Aldrich). The longitudinal study of PAH was
carried out by weekly evaluations of the RV-PA hemo-
dynamics for up to four weeks post injections. The treated
rats studied after one week of the injection (PAH1) represent
the early stage whereas the group studied after four weeks of
receiving the injection (PAH4) corresponds to the late stage
of PAH. A control group was injected with saline matching
the volumetric dose of the treated group. To account for the
aging effects, the control group (NCTL¼ 7) consisted of ani-
mals injected after one, two, three, or four weeks
(NCTLweek1¼ 1, NCTLweek2¼ 2, NCTLweek3¼ 3,
NCTLweek4¼ 1). When possible, a treated PAH animal was
paired with a control (CTL) animal and housed together for
up to four weeks. The group sizes for each disease stage were
NPAH1¼ 8, NPAH2¼ 8, NPAH3¼ 6, and NPAH4¼ 16.
In-vivo hemodynamic studies
The paired rats underwent surgery the same day, one after
another. The animals were anesthetized using isoflurane
(Henry Schein, NY, USA). Anesthesia was initially
administered by placing the animal in an induction chamber
supplied with oxygen mixed with 4% isoflurane. When the
animal was confirmed to be unconscious, the anesthesia was
decreased to 2.5% and supplied via a nasal cone. Following
a tracheotomy, the rat was intubated (E-Z Anesthesia
Ventilation System, Palmer, PA, USA) and supplied with
a respiratory rate of 50 breaths per minute and a tidal
volume based on the animal’s weight.5 The heart and
great vessels were exposed via a thoracotomy. Once the
chest cavity was opened and the RV was identified, a 21-
gauge needle was used to puncture the ventricular wall api-
cally. The needle was immediately replaced by a 1.9F PV
admittance catheter (Transonic Scisense, ON, Canada)
introduced along the long axis of the chamber. Once PV
waveforms recorded were reproducible in steady state
(steady-state conditions), the inferior vena cava (IVC) was
slowly occluded with a suture line (Fine Science Tools
Braided Silk Suture 5-0, Foster City, CA, USA) for a few
seconds to change the venous return (occlusion conditions).
On average, five occlusions were performed on each animal.
Following PV measurements, a second puncture was made
on the RV base next to the outflow track using a 23-gauge
needle. A 1.6-F dual-pressure sensor catheter (Transonic
Scisense, ON, Canada) was inserted into the RV and
advanced into the main pulmonary artery (MPA) via the
pulmonic valve for simultaneous measurements of the RV
and MPA pressures. The MPA pressure time series was used
to calculate mPAP and thus confirm PAH. At the conclu-
sion of the hemodynamic measurements, the animals were
exsanguinated and the heart and lung vessels were flushed
with phosphate buffered saline (PBS; 0.14M NaCl; 0.0027M
KCl; 0.0017M KH2PO4; 0.01M Na2HPO4) and heparin
(Fresenius Kabi, USA). Data were collected in LabChart
Software (AD Instruments Inc., Version 8.0 Pro, Colorado
Springs, CO, USA).
Hemodynamic metrics such as SV, ejection fraction (EF),
heart rate (HR), CO, total PVR, and ventricular relaxation
time constant s were computed through a custom-written
MATLAB (Mathworks Inc, Version 8.6.0, Natick, MA,
USA) code. The end-systole (ES) point was determined by
finding the maximum value of the pressure to volume ratio
in a given pressure-volume loop. The end-diastole (ED)
point was the first point in the pressure-volume loop with
highest volume and lowest volume rate of change (i.e. dV/dt
0). Based on the difference in volume at ED and ES, SV
was calculated. EF was determined by the ratio of SV and
ED volume. Using the calculated SV and HR, CO was
computed by taking the product of the two. Total PVR
was computed as the ratio between RV ES pressure and
CO.6 The RV relaxation time s was calculated by fitting
an exponential decay function to the pressure waveform
p tð Þ ¼ P1 þ P0  P1ð Þet from the point dP/dtmin occurs
until the end of systole (or when the pulmonic valve
closes). Here the zero-asymptote assumption is neglected.
Instead, P0 is the pressure at time of dP/dtmin and P1 the
pressure of a fully relaxed ventricle held at its end-systolic
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volume.7,8 To quantify ventricular hypertrophy, the RV
weight was normalized to the sum of the left ventricle and
septum weight (Fulton index6). Hypertrophy of the RV was
considered established if the Fulton index ratio was> 0.25.9
RV wall thickness was measured in three different locations
along the wall using a thickness gauge (1010Z, Starrett,
Athol, MA, USA, with a range of 0–0.375’’ and accuracy
of 0.001’’) and averaged for each animal.
Right-ventricular and pulmonary vascular elastances
Ventricular contractility or end-systolic elastance Ees corres-
ponds to the slope of the linear regression to the end-systolic
points during occlusion of the IVC (approximately 40%
drop in blood pressure). Based on the steady-state PV meas-
urements, the effective pulmonary arterial elastance Ea or
the slope of the line between the ES point and ED volume
at zero pressure was obtained. Ea is a parameter that relates
to the ability of the pulmonary vasculature to buffer the
incoming blood pressure and volume influx. By taking the
ratio of Ees and Ea, the ventriculo-vascular coupling g can
be assessed.10 Finally, passive ventricular chamber stiffness
was calculated by fitting the ED PV data points during
occlusion of the IVC using the following exponential
function P Vð Þ ¼ eV. Here,  is the diastolic stiffness con-
stant and  is a curve fitting constant. End-diastolic ela-
stance Eed was determined by evaluating chamber stiffness
(dP=dV ¼ eV) at the ED point during PV steady-state
conditions.
Relating ventricular pressure-volume to ventricular wall
mechanics at ES and ED
To compute RV end-diastolic and end-systolic pressure-
volume relations from RV geometry and myocardial resting
and active material properties, a spherical model of the RV
was developed. The RV model comprehends the RV cavity,
RV free wall, and septum. Assuming that the RV is a frac-
tion of a sphere with an outer radius R, the volume of the
sphere is the sum of the RV free wall volume Vw, the septum
volume Vsw, and the RV cavity volume VRV, viz.,
kr
4
3
R3 ¼ Vw þ VRV þ Vsw ð1Þ
This formulation assures that the radius of the cavity is
not zero when the RV volume VRV is zero. The fraction of
Table 1. Summary statistics of hemodynamics, elastances, and RV structural changes observed during PAH progression.
Parameter
CTL
(n¼ 7)
PAH1
(n¼ 8)
PAH2
(n¼ 8)
PAH3
(n¼ 6)
PAH4
(n¼ 4)
Fulton Index 0.24 0.04 0.31 0.05 0.34 0.04* 0.47 0.1*,y 0.52 0.03*,y,z
RV weight (g) 0.22 0.04 0.23 0.04 0.3 0 0.37 0.05 0.47 0.05*,y
RV thickness (mm) 0.61 0.08 0.59 0.1 0.6 0.08 1.03 0.07*,y,z 1.12 0.12*,y,§
Animal’s weight (g) 268 23.3 262.1 43.2 293 18.1 267.3 24.6 283.7 24.9
ESP (mmHg) 31.7 6.1 27.3 2.4 39.5 6 52.3 7.3y 70.5 6.8*,y
ESV (mL) 90.8 19.3 79.2 19.3 109.7 37 126.1 25.9 140.9 35.6y
EF (%) 62.3 6.7 64.2 6.4 61 7.6 53.6 9.9 53.9 5.4
CO (mL/min) 41.2 3.5 40.5 8.4 51.7 10.8 45.9 13.5 45.5 3.4
SV (mL) 149 16.7 141.1 22.9 165.9 24.5 148.3 38.3 160.3 6
dP/dtmax (mmHg/mL) 1603.8 316.2 1492.4 242.4 1933.4 394.8 2082.6 123.9y 2680.3 311.5*,y,z
HR (bpm) 278.5 26 286.7 40.7 311.2 39.2 307.4 17.5 284.2 23.6
mPAP (mmHg) 24.3 4.9 25.2 2 32.6 4.8* 34.3 4.6* 42.8 4.9*,y,z
Total PVR (mmHg/mL.min) 0.8 0.2 0.7 0.2 0.8 0.2 1.2 0.4 1.6 0.2y
EDP (mmHg) 4.6 0.7 3.5 1.4 4.6 1.4 5.4 2.3 7.7 1.7y,z
EDV (mL) 239.7 19.6 220.3 31.6 275.6 49.5 274.4 36.7 301.3 37.8y
dP/dtmin (mmHg/mL) 1274 349.4 1079.2 172.3 1462.6 308.2 1876.9 233.7*,y 2080.6 237.7*,y,z
s (ms) 15.1 3.4 13.6 2.8 14.7 4 12.8 1.4 11.1 3.4
Ees (mmHg/mL) 0.25 0.08 0.25 0.11 0.25 0.09 0.34 0.1 0.45 0.13*,y,z
Ea (mmHg/mL) 0.2 0.06 0.21 0.06 0.24 0.04 0.4 0.16 0.42 0.07*,y
Eed (mmHg/mL) 0.03 0.013 0.015 0.006 0.019 0.011 0.027 0.023 0.033 0.005
g 1.31 0.52 1.25 0.67 1.05 0.39 1.06 0.6 1.11 0.3
*P< 0.05 vs. CTL.
yP< 0.05 vs. PAH1.
zP< 0.05 vs. PAH2.
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the sphere kr that best matched the measured mean RV
masses and wall thickness (Table 1) was found to be 0.6.
Vw and Vsw were computed using the measured RV wall
mass and 45% of the LV wall mass divided by myocardial
density 1.053 g/mL.11 The 45% is an estimate of the LV wall
mass occupied by the septal wall based on experimental
observations. Sensitivity analysis of the geometric param-
eters kr, which was in the range of 0.4–0.8 and septum
wall percentage of 25–60%, were found not to affect the
final conclusions drawn from this model.
At the unloaded volume, VRV¼V0 and R¼R0, so that
R0 ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
V0 þ Vw þ Vsw
kr
4
3
3
s
ð2Þ
V0 was estimated from the in-vivo measurements. Based on
the assumption that ED pressure at V0 is zero and the
physiological constraint of V0 being positive at ED, the
measured ED pressure was normalized, i.e. the minimum
ED pressure value was subtracted from the raw data.
Hence, V0 was estimated to be the mean value of volumes
at zero ED pressure.
The radius R and wall thickness h of the spherical model
in terms of V0 and R0 are computed as:
R ¼ R0
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
VwþVRV þ Vsw
V0 þ Vw þ Vsw
3
r
, and h ¼ Vw
kr4R
2
ð3Þ
To avoid over-restricting the model geometry, the experi-
mentally measured wall thickness was not directly incorpo-
rated in the computational modeling. Instead, Eq. 3 for wall
thickness was used. A schematic of the model is illustrated
in Fig. 1.
For sarcomere mechanics,12 the myocardium passive
stress was defined as
Tp ¼ k1 ek2 1ð Þ  1
 
where  ¼ Ls
LR
¼ r
r0
ð4Þ
k1 and k2 are material parameters, where k1 is a stiffness
coefficient.  is the stretch ratio of sarcomere length Ls to
reference length (LR¼ 1.95mm) measured from the mid-wall
radius r ¼ R h2. Based on the model used by Guccione
et al.’s work, the myocardium active stress at ES13,14 was
defined as follows
Ta ¼ Tmax Ca
2
0
Ca20 þ Ca
2
max
eBðLsL0 Þ1
ð5Þ
where Tmax is maximal isometric tension achieved at the long-
est sarcomere length and maximum peak intracellular
calcium concentration (Camax ¼ 4:35mM).13 Ca0, set to
0.25mM, is the peak intracellular calcium concentration, L0
or 1.50mm is the sarcomere length at which no active tension
develops, and B is the scale that determines the shape of peak
isometric tension-length relation. The material parameters of
the resting and active sarcomere length-tension relations L0,
LR, Ls, Cao, and Camax were constrained to previously mea-
sured constants, and k1, k2, Tmax, and B were determined by
fitting the model to measured RV PV relations.
Given that the RV wall is thin compared to its cavity
radius,15 the thin-walled LaPlace’s law was used to estimate
mean mid-wall stresses. Here, the RV cavity blood pressure
P is computed as
P ¼ 2Th
r
where the ventricular wall stress T is the sum of the active
and passive stress (T¼TaþTp) generated at the sarcomere
length, Ls. For EDPVR, the total tension equals passive
tension (i.e. no active tension at ED).
To predict ESPVR and EDPVR, PV data from each indi-
vidual animal obtained during IVC occlusions were fitted
using the linear and exponential functions described in the
previous section. Using the fitted functions corresponding to
each individual animal over a common pressure and volume
range, a mean standard error curve was generated to rep-
resent the measured data per group. While keeping the par-
ameters L0, LR, Ca0, and Camax constant, the material
property parameters C ¼ kC1 , kC2 , TCmax, BC
 
were adjusted
to match the ESPVR and EDPVR interpolated data of the
control group. The values of C were initialized based on
reported values and modified while assuring that the result-
ant length-stress relationship was within the physiological
ranges reported for rat RV by ter Keurs et al.16 The geo-
metric variables Vw, Vsw, and V0 were measured directly in
our experiments or derived directly from measurements
Fig. 1. Schematic of the RV computational model modeled as a frac-
tion of a sphere of outer radius R and mid-wall radius r. In a cross-
section of the sphere, the RV cavity VRV, RV free wall Vw, and septum Vsw
volumes illustrate the different compartments of the RV model.
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using relationships given here. The RV model with different
geometries for each group was reflected by different V0 and
wall masses (Vw, Vsw), first with the control group material
parameters C, and then with a new set of adjusted material
parameters. All the RV computational model calculations
were carried out in Python computing environment
(version 3.6).
Statistical analysis
Descriptive statistics were computed for all the hemo-
dynamic measurements, RV tissue measurements, and
elastances. To detect significant differences among groups,
non-parametric Wilcoxon/Kruskal–Wallis (Chi-square
approximation) tests were conducted in cases where obser-
vations displayed departures from a normal distribution;
otherwise, parametric analysis of variance was carried out.
When a difference in treatment was found to be significant,
multiple group comparisons were then conducted to identify
where the differences occurred between the groups (CTL,
PAH1, PAH2, PAH3, PAH4). Multiple comparisons
Tukey HSD were used for the normally distributed data;
otherwise the Dunn Method was implemented. All the stat-
istical analyses were carried out in JMP Pro Statistical
Software (version 13.0.0, ! SAS Institute Inc., Cary, NC,
USA). For all statistical tests, significance level was set at
0.05. All values are presented as mean standard deviation,
unless specified.
Results
Animal preparation
Out of 38 animals administered with MCT, 26 developed
PAH. Two animals were normotensive, four unexpectedly
died at the beginning of the surgical procedure unable to
confirm PAH, and six died between weeks 3 and 4 post
injection. RV samples and weights were collected from the
19 out of 26 treated and six out of seven control animals.
In-vivo hemodynamics
The PV loops from each group exhibited unique hemo-
dynamic characteristics. The CTL group exhibited a
square-shape loop through the four weeks with tight systolic
pressure (31.7 6.1mmHg) and volume ranges (90.8 19.3
to 239.7 19.6mL). In the case of the treated animals, RV
ES pressures rose each week from 27.3 2.4 up to
70.5 6.8mmHg (P value¼ 0.0004). ED pressures also
increased, significantly in the late PAH group (from
3.5 1.4 to 7.7 1.7mmHg, P value¼ 0.028, PAH4 vs.
PAH1). While the width of the PV loops or SV remained
statistically the same (from 141.1 22.9 to 160.3 6 mL),
there was a shift to the right of ES volume (from 79.2
19.3 to 140.9 35.6 mL, P value¼ 0.0190) and ED volume
(from 220.3 31.6 to 301.3 37.8 mL, P value¼ 0.0189) as
weeks advanced, indicating the enlargement of the ventricle
and an increase in resting volume. CO was also maintained
in disease and remained statistically the same for all groups.
The increase in mPAP (from 25.2 2 to 42.8 4.9mmHg,
P value¼ 0.0001) and total PVR (from 0.7 0.2 to
1.6 0.2mmHg/mL min, P value¼ 0.0149) was reflected
in the PV loop shape by producing the formation of a shoul-
der during the ejection phase (slanted/triangular shape). The
increase in ED volume and preserved SV caused a slight
decrease in EF (64.2 6.4% to 53.9 5.5%). Ventricular dia-
stolic function parameters dP/dtmin and  decreased, with a
statistically significant difference only found for dP/dtmin at
the late disease stages (vs. normotensive and early PAH,
P< 0.0001). Summary statistics of the hemodynamic meas-
urements are shown in Figs. 2 and 3 and Table 1.
Right-ventricular morphology
Right ventricular morphology changed with the progres-
sion of the disease (Fig. 2). The ventricle progressively
became hypertrophic (Fulton index from 0.31 0.05 to
0.52 0.03, P value¼ 0.0011, RV weight from 0.23 0.04
to 0.47 0.05 g, P value¼ 0.0316) and thickened signifi-
cantly (from 0.6 0.1mm in the normotensive group to
1.1 0.1mm in advanced PAH, P value< 0.0001) by week
2 post treatment. The weight of the animals, however,
remained the same.
Right-ventricular and pulmonary vascular elastances
Effective arterial elastance Ea significantly increased at the
late PAH stages (PAH3 and PAH4 groups). Ees initially did
not change (CTL, PAH1, and PAH2 groups) but then
increased significantly in the PAH3 group (0.25 0.08 to
0.34 0.1mmHg/mL, P value¼ 0.0435) and further
increased in PAH4 (0.45 0.13mmHg/mL, P value¼ 0.0460
vs. CTL). End-diastolic elastance Eed dropped initially
(CTL: 0.030 0.01 to PAH1: 0.015 0.006mmHg/mL),
but then progressively increased reaching baseline value at
week 4 (0.033 0.005mmHg/mL).  and  were not statis-
tically different across the groups.  was unaffected at the
early PAH stages and displayed an increase after three
weeks of MCT treatment. Diastolic chamber stiffness ,
on the other hand, decayed in the first week of MCT treat-
ment and remained overall constant until late PAH. The RV
and pulmonary system remained coupled during the pro-
gression of PAH. This was reflected in the ventricular-
vascular coupling efficiency g, which was not statistically
different among the treatment groups. Ees, Ea, Eed, and g
are summarized in Fig. 4.
Ventricular hemodynamics related to ventricular wall
mechanics at ES and ED
The RV model was able to recapitulate the experimentally
measured mean RV pressure-volume relations at ES and ED
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(Fig. 5a, left). Using geometric measurements from PAH
groups (solid lines), the RV model with the control-group
material properties overestimated EDPVR at week 1, closely
matched the mean EDPVRs measured in the PAH groups at
weeks 2 and 3, and underestimated EDPVR at week 4. The
ESPVR model predictions were highly underestimated for
the week 2, 3, and 4 PAH groups. However, when account-
ing for the geometrical changes and adjusting the material
properties k1 and Tmax to increase intrinsic myocardial
passive and active tension development, predictions from
the model (dashed line) all showed good agreement with
experimentally measured mean ESPVRs across the ranges
of volumes measured in the PAH groups. Similar findings
and the same conclusions were obtained when the entire
analysis was repeated with altered assumed fraction of
septal wall in the LV wall mass. Model parameters are
shown in Table 2, with the adjusted k1 and Tmax values to
account for a given PAH group material properties.
Fig. 2. Summary statistics of cardiac performance during systole (a) and diastole (b). *P< 0.05.
Fig. 3. Summary statistics of RV hypertrophy evidenced with Fulton Index, RV thickness, and RV weight. (a) No changes in animal weights are
shown. (b) mPAP and total PVR. *P< 0.05.
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Fig. 5. (a) Comparison of measured raw (open circles) and averaged (blue dots and bars) right-ventricular end-diastolic and end-systolic
pressure-volume relations with computational model predictions. Control: Model-predicted end-diastolic and end-systolic PV relations (squares
and gray lines) using control-group geometry and control-matched material properties. PAH1-4: Model-predicted end-diastolic and end-systolic
PV relations (squares and gray lines) using control-group geometry and control material properties. Model-predicted end-diastolic and end-
systolic PV relations (solid lines) using PAH geometry and control material properties. Model-predicted end-diastolic and end-systolic PV
relations (dashed lines) using PAH geometry and PAH-matched material properties. (b) Model-predicted isometric end-systolic and end-diastolic
sarcomere length-tension relations for all 5 animal groups determined by optimizing material parameters to match measured RV pressure-volume
relations. Note the increase in predicted systolic sarcomere elastance 2–4 weeks after MCT. End-diastolic sarcomere stiffness tension decreases
at week 1 of PAH and increases by.
Fig. 4. (a) Representative occlusion PV loops of control and after 4 weeks of MCT administration (chronic PAH). Ees: slope of dashed black line
(ESPVR); Ea: slope with dashed dark gray line; Eed: slope with light gray line. (b) Summary statistics of Ees, Ea, Eed, and g are also depicted.
*P< 0.05.
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Based on the RV model predictions of ESPVR and
EDPVR with the adjusted parameters (Table 2), active
and passive sarcomere length-stress curves were generated
for each treatment group. As shown in Fig. 5b, the control,
PAH2 and PAH3 passive length-stress curves closely over-
lap. However, there was a decrease in muscle stiffness in
PAH1 (from k1¼ 2.3 to 1.4mmHg) and a large increase in
muscle stiffness at PAH4 (from k1¼ 2.3 to 3.5mmHg).
The active sarcomere length-stress relation in the control
and PAH1 groups were the same. However, this relation
changed for the PAH2 group, where the contractility of
the muscle increased—from Tmax¼ 640 to 1300mmHg—
and remained high (Tmax¼ 1100 and 1200mmHg) in the
following weeks.
To discriminate the contributions of RV geometric
remodeling from changes in diastolic and systolic myocar-
dial material properties on the preservation of RV SV,
the model was used to compute RV end-diastolic and end-
systolic pressure-volume relations using three combinations
of model geometry and material properties (Fig. 6): control-
group geometry and material properties (dotted lines in
Fig. 6b); PAH geometries and control material properties
(solid lines in Fig. 6b); PAH geometries and PAH material
properties (dashed lines in Fig. 6b). From these computed
ED and ES PV relations, SVs were computed to quantify
how the changes in hemodynamics, wall geometry and pas-
sive and active myocardial material properties combined to
maintain CO in the presence of altered RV hemodynamics.
The SV labeled SV1 in Fig. 6b represents the SV predicted
under PAH loading conditions if there had been no geomet-
ric remodeling or changes in myocardial diastolic or systolic
material properties. Without compensatory changes in ven-
tricular geometry, elastic and contractile properties, the
steep decrease in SV1 indicates that right ventricular func-
tion would have been reduced by 75% after four weeks, and
that elevated RV EDP had not been sufficient to compensate
after week 1. SV2 is the SV computed when the contribution
of geometric remodeling on the EDPVR was accounted for
in the models. It shows that RV dilation after week 1 was a
major contributor to the preservation of RV SV. The con-
tribution of altered geometry and diastolic compliance on
the EDPVR is represented by SV3. The transient decrease in
RV myocardial stiffness was the major compensatory mech-
anism at week 1, but after week 1, the contribution of
altered RV passive stiffness was minor and actually negative
as the myocardial stiffness increased by week 2. SV4 repre-
sents the contribution to maintenance of SV of diastolic
material and chamber remodeling and the effects of geomet-
ric remodeling on the ESPVR. Subtracting SV3 shows that
the effects of changes in ventricular geometry on the ESPVR
actually worked slightly against compensation. The increase
in ventricular radius that increased ED volume was not fully
overcome by the increase in RV wall thickness. Finally,
when the effects on SV of chamber remodeling and diastolic
and systolic material properties on both the EDPV and
ESPV relations were all included in the model (SV5), the
additional effect of increased contractility was also shown
to be an important compensatory mechanism. In summary,
the effects of geometric remodeling on the EDPVR and of
increased myocardial contractility on the ESPVR were the
major mechanisms by which SV was preserved in the setting
of elevated PAP, and both mechanisms contributed equally
during weeks 2–4. In week 1, the minor loss of SV that the
modest hemodynamic changes would have caused was fully
compensated by a transient decrease in diastolic myocardial
stiffness before any geometric remodeling or contractile
compensation had begun.
Discussion
In the present study, RV hemodynamic and morphological
measurements were taken to investigate the compensated
Table 2. Parameters used in the computational model of the RV to predict PV relations at end-systole and end-
diastole.
Parameter CTL (n¼ 7) PAH1 (n¼ 8) PAH2 (n¼ 8) PAH3 (n¼ 6) PAH4 (n¼ 4)
V0 (mL) 91.76 106.25 152.39 195.55 185.87
Vw (mL) 209 218 218 351 446
Vsw (mL) 385 308 376 321 385
kc1 (mmHg) 2.3 2.3 2.3 2.3 2.3
k1 (mmHg) – 1.4 2.0 2.3 3.5
kc2 30 30 30 30 30
Tcmax (mmHg) 640 640 640 640 640
Tmax (mmHg) – 640 1300 1100 1200
Bc (mm1) 10 10 10 10 10
The morphology parameters V0, Vw, Vsw are the unloaded volumes, RV free wall volume, and volume of septum wall, respectively. The
material property parameters C¼ {k1C, k2C, TCmax, BC} are based on the model predictions of ES PV and ED PV of the control animals.
When changes in morphology did not match ESPVR and EDPVR, this gave rise to a new set of adjusted material properties – in this
case, k1 and Tmax.
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phase of RV hypertrophy in the MCT-animal model of
PAH. Our goal was to discriminate the contributions of
ventricular geometric remodeling and intrinsic changes in
myocardial mechanical properties at ES and ED to the
maintenance of CO using a computational model. In this
longitudinal study, the myocardium was found to initially
decrease its stiffness—an acute adaptation that preserved SV
at week 1 of PAH induction and reversing by week 2.
This transient early decrease in diastolic stiffness allowed
the RV to soften initially in order to preserve diastolic filling
and therefore maintain SV. By week 2, the PAP, PVR, and
end-systolic volume all increased while maintaining SV, CO,
and EF. This compensated response could be explained in
the model almost entirely by the changes in chamber volume
and mass. However, after week 2, the changes in RV volume
and wall thickness and increased filling were not sufficient to
maintain SV and CO as PAP continued to increase. This led
us to conclude that there was a significant increase in RV
contractility during this period as shown by the increased
Tmax values required to match the experiment-derived
ESPVR. Furthermore, this MCT-PAH rat is a model of
RV compensation during the first month after treatment,
where geometric remodeling on EDPVR and increased myo-
cardial contractility on ESPVR are the major mechanisms
by which SV is preserved in the setting of elevated PAP. The
mediators of this compensation might themselves promote
longer-term adverse remodeling and decompensation in this
animal model.
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Fig. 6. (a) Model-predicted changes in RV SVs from weeks 1–4 due to: (SV1) changes in preload and afterload only; (SV2–SV1) the additional
contribution of geometric remodeling on the EDPVR; (SV3–SV2) the further contribution of altered diastolic compliance on the EDPVR;
(SV4–SV3) the further contribution of geometric remodeling on the ESPVR; (SV5–SV4) the further contribution of altered contractility on the
ESPVR. (b) Graphical definitions of model-predicted SVs SV1–SV5 obtained from model-predicted EDPVR and ESPVR computed using: control-
group geometry and control-group material properties (dotted lines); PAH geometries and control material properties (solid lines); PAH
geometries and PAH material properties (dashed lines).
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MCT-model of PAH shows features of preserved cardiac
function
In our study, RV pressures rose and volumes increased while
maintaining CO, SV, and EF. Our results are in agreement
with Handoko et al.,17 where CO was preserved in rats with
no significant difference in total PVR by day 14 after MCT
injections. In their study, like ours, by day 28 after MCT
injections, there was a significant increase in total PVR while
CO continued to be preserved. Yin et al. also reported main-
tenance of EF and CO in their four-week of MCT-rat
model.18 In addition to CO being preserved, Werchan
et al. also measured significant decrease (more negative
values) in dP/dtmin in four-week MCT-treated rats.
19
Like Werchan et al., magnitude of the rate of pressure
change during relaxation (dP/dtmin) became significantly
more negative, but relaxation time s only slightly decreased
in advanced PAH. This discrepancy has been previously
reported by Umar et al., where no change in the relaxation
time s was found in the presence of an increasing trend in
dP/dtmin magnitude
20 or vice versa by Correia-Pinto et al.
in MCT-induced PAH rats.21 These findings suggest that in
the four-week MCT model, the RV maintains diastolic func-
tional elasticity and is still in a compensatory phase.
The work by Handoko et al. showed that after these four
weeks, there is a statistically significant decline in CO, indi-
cating the end of the RV compensation phase.
Sudden deaths between week 3 and week 4 after MCT
injections occurred in our study. MCT is a toxic alkaloid
that when ingested produces a syndrome characterized by
pulmonary hypertension, pulmonary vasculitis, and RV
hypertrophy.22 To date, the toxicological mechanisms of
the MCT in the lung are unknown. Abe et al. have suggested
that MCT-injected rats probably die of cardiac and renal
dysfunction.23 In a study by Umar et al. they reported
sudden death in their 30% death rate 23 days after MCT
injections and 100% by day 32 post injections, attributing
this to spontaneous ventricular fibrillation.24 Several groups
have reported varying rates after three weeks of treat-
ment.25–28 Some prominent studies indicate the presence of
a proarrhythmic substrate in hearts of MCT-treated rats,
and among the causes of sudden death are the changes in
Ca2þ and Kþ channel activity and electrical restitution.29–32
Pulmonary arterial stiffness increases in late PAH
Pulmonary arterial stiffening markedly increased and
became significantly different from the control group to
the MCT-injected rats after three weeks. Pulmonary arterial
elastance Ea values increased as PAH advanced, which has
also been reported by other groups when using the rat MCT
model: Yin et al. from 0.5 0.14 to 0.79 0.3mmHg/mL;18
and de Man et al. from 0.15 to 1.0mmHg/mL.33 Total PVR
increased by twofold in our studies, which suggests the
pruning of pulmonary vessels. While we did not carry out
a histological analysis, Yin et al. did in MCT-treated
animals after four weeks of injections. In their histological
analysis of the lungs, the pulmonary arterioles showed
marked lesions (i.e. thickening, narrowed, and inflamed
arterioles18), all consistent with characteristics found in
PAH patients.
Ventricular contractility and stiffness in PAH cannot be
explained by morphological changes alone
SV could only be maintained after two weeks of MCT treat-
ment by the significant increase in end-systolic elastance.
Increase in Ees has been previously reported to increase by
Yin et al. (from 0.67 0.12 to 0.95 0.42mmHg/mL),18 de
Man et al. (from 0.2 to 0.5mmHg/mL),33 and Blaudszun
et al. (from 0.24 0.12 to 0.56 0.33mmHg/mL)34 from
normo- to hypertensive states in MCT-models of PAH in
rats. The model analysis showed that wall thickening and
geometric remodeling alone were unable to explain all of the
increased chamber elastance. The RV model used to predict
ESPVR underestimates the data measured at ES of the
PAH2, PAH3, and PAH4 groups unless the material par-
ameters were adjusted and the maximal isometric tension
Tmax is increased by twofold. Predicted peak systolic
stress-strain relations showed that intrinsic myocardial con-
tractility increased significantly by week 2 and remained sig-
nificantly higher than the control group. Rain et al.1 found
that active tension of RV myocytes from PAH patients was
higher than those of normotensive subjects. Interestingly,
CO in the PAH group was lower than the control group
but without reaching statistical significance. Sabourin
et al. studied RV cardiomyocytes from a three-week rat
MCT model of PAH and in this group of hypertrophied
RV myocytes found an increase in the expression of
SERCA2 and the amplitude of calcium transients, which
resulted in an increase in contractility. This would explain
the results from our model analysis and Rain et al.’s meas-
urements in samples from PAH patients. Sabourin et al.
concluded that enhanced SR calcium load was mediated
by STIM1L and TRPCs/Orail. The parallel in these studies
indicates that MCT is a valuable model of PAH for mimick-
ing the initial RV adaptation found in PAH patients.2
In our study, we observed a transient decrease in Eed after
one week of PAH, followed by a recovery to control values
during PAH progression. The RV model analysis suggests
that this initial decrease was due to a temporary increase in
myocardial compliance. This myocardium intrinsic change,
along with RV wall thickening as hypertrophy progressed,
contributed to the restoration of end-diastolic chamber
stiffness subsequently. The temporary increase in diastolic
myocardial compliance followed by the subsequent increase
in ED pressure contributed significantly to the maintenance
of SV via the Frank-Starling mechanism by increasing
end-diastolic volume. In humans with PAH, RV diastolic
stiffness Eed has been shown to be sensitive to the stage of
the disease. Trip et al. reported an increase in Eed from
control (0.25mmHg/mL) to PAH patients.3 In their
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study, they determined that diastolic stiffening of the RV
is independent of the systolic adaptation process. They
also suggested that Eed increment in PAH patients with a
survival> 5 years may be explained by the hypertrophy of
the RV, while in patients with< 5 years such increase
may be related to additional intrinsic alterations of the
myocardium. One possible mechanism of the acute loss of
myocardial stiffness may be an increase in the fraction of the
more compliant N2BA isoform of titin as a fraction of total
titin, as was reported by Rain et al.35 in rats after seven
weeks of mild PA banding. While Eed was not statistically
different from the control and PAH4 groups, the model
shows an increase in EDPVR stiffness and points towards
stiffening of the passive sarcomere length-tension relation,
which rose in PAH4.
Ventriculo-vascular coupling in PAH remains unaffected
Several studies have used g to evaluate the adaptation and
performance of the RV during PAH. In a study carried out
by de Man et al. in a MCT-induced PAH rat model, they
reported a decrease in g from the control to severe disease
state (from 1.0 to 0.5).33 Even though Yin et al. used the
same animal model, they reported no change in g when
comparing normo- to hypertensive MCT rats (control:
g¼ 1.44 0.08, PAH: g¼ 1.42 0.33).18 Our outcomes
showed that the RV and the pulmonary arteries are coupled
through the disease progression, indicating that the heart is
still keeping up with the high-pressure overload. Here, we
found a hypertrophic heart, with an increase in ES volume
and ED volume but a preserved SV, no change in CO, EF
nor HR. CO is preserved even though the resting volume of
the RV increased. This supports the claim that the RV is still
in the adapting phase and working along the increase in PA
pressures.
Limitations
Hemodynamic measurements were carried out using isoflur-
ane as an anesthetic during open-chest surgery. Some studies
have shown that isoflurane can affect hemodynamics
measurements by reducing PAP, total PVR, and contractil-
ity.36,37 Ewalenko et al. demonstrated that while true that
pulmonary vascular tone decreased with isoflurane com-
pared to propofol, this decrease was negligible and did not
affect impedance. Given that all animals underwent the
same in-vivo measurements, and there was a statistically sig-
nificant difference in mPAP and total PVR across the
groups, we think that the effects of isoflurane can be neg-
lected. Open-chest surgeries may produce an artifactual
reduction of right ventricular pressure.38 Pacher et al. have
shown that it is feasible to obtain similar results in open- vs.
closed-chest surgery, if body temperature, fluid balance, and
anesthesia are adequately regulated and monitored during
the surgical procedure,5 which we carefully monitored in our
experiments. Given that the study focused on RV mechanics
and hemodynamics and relied on the literature for expected
biological changes, no biological data are presented.
Although the RV wall is not a membrane and the thin-
walled assumption is less well justified when the wall thick-
ens in PAH, the wall thickness to radius ratio did not exceed
0.14, and the model was only used to estimate global pres-
sure-volume relations not non-homogeneous myocardial
stress distributions. To compute RV end-diastolic and
end-systolic pressure-volume relations from RV geometry
and myocardial resting and active material properties, a
spherical model of the RV was adapted from the more com-
prehensive biventricular TriSeg model.37 Like previous
works,12,13 our model includes length-dependent calcium-
sensitivity mechanics. However, we simplified the TriSeg
model to exclude the LV, ventricular interactions, and cir-
culatory dynamics because the current study was only
focused on the effects of RV geometry and material proper-
ties on PV relations and because all the hemodynamic and
structural data necessary to parameterize the more compre-
hensive model were not measured. In spite of these simpli-
fications, the model was able to recapitulate the
experimentally measured mean RV pressure-volume rela-
tions, using sarcomere length-tension relations similar to
those reported in rat cardiac trabeculae by ter Keurs et al.16
Conclusion
In conclusion, these results suggest the MCT-animal model
at four weeks at 60mg/kg is a model of RV compensation.
At week 1, SV was maintained by the RV decreasing its
diastolic chamber stiffness, not via changes in systolic func-
tion. However, by week 2 that mechanism was not enough:
diastolic function had reversed closer to baseline and
increased contractility was needed as the RV pressures
started to rise. Changes in the EDPVR (i.e. decrease in
passive tension) could also be an effect of monocrotaline
as there was no change/increase in pressure. By week 2,
however, the RV contractility increases (increase in active
sarcomere tension) in order to maintain SV and CO.
Interestingly, by weeks 3 and 4, the RV does not appear
to need to recruit as much muscle fibers because the ventricle
started to remodel. Hence, the effects of geometric remodel-
ing on the EDPVR and of increased myocardial contractility
on the ESPVR were the major mechanisms by which SV was
preserved in the setting of elevated PAP, and both mechan-
isms contributed equally during weeks 2–4. Therefore, com-
pensated right ventricular function depends on chamber
remodeling and contractile augmentation in the onset of
PAH in this rat animal model.
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